# Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet

> **NCT03389061** · PHASE4 · WITHDRAWN · sponsor: **Radboud University Medical Center**

## Conditions studied

- HCV

## Interventions

- **DRUG:** sofosbuvir/velpatasvir tablet
- **DRUG:** sofosbuvir/velpatasvir crushed

## Key facts

- **NCT ID:** NCT03389061
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-04-01
- **Primary completion:** 2019-03-22
- **Final completion:** 2019-03-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of patients who are eligible for inclusion: less patients on treatment and not using epclusa.
- **Last updated:** 2020-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03389061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03389061, "Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03389061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*